Company Overview - Xeris is a fast-growing commercial biopharma company with three commercial products on the market [1] - The products include Gvoke for hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for hypercortisolemia and Cushing's syndrome [2] Product Portfolio - Gvoke is a rescue pen for hypoglycemia, similar to an EpiPen for diabetics [1] - Keveyis treats an ultra-rare hereditary genetic disorder known as primary periodic paralysis [2] - Recorlev is focused on hypercortisolemia and Cushing's syndrome, identified as a significant growth driver for the company [2] - The company is also developing XP-8121, a once-weekly subcutaneous levothyroxine for hypothyroidism, which is ready for Phase III trials [2]

Core Insights - The company achieved financial self-sustainability, eliminating the need for external funding to support its current strategy and pipeline [1] - Recorlev served as the primary growth engine, nearly doubling its patient base to approximately 700 patients by year-end 2025 [1] - Gvoke provided durable revenue growth of 14% for the full year, supported by broad market access and alignment with treatment guidelines [1] - Keveyis exceeded expectations by increasing the average number of patients on therapy through comprehensive patient support services [1] - Operating leverage improved significantly, leading to the company's first full year of net income and nearly $60 million in adjusted EBITDA [1] - Management attributed the 44% full-year revenue growth to disciplined execution and broad-based demand across all three commercial products [1] - The company doubled its Recorlev commercial footprint in January 2026 to enhance patient support and sales interactions for long-term growth [1]

Core Insights - The company experienced significant growth in 2025, with total revenue increasing by 44% year-over-year to approximately $292 million, driven by strong demand across all three commercial products: Recorlev, Gvoke, and Keveyis [3][14][18] - Recorlev was identified as the primary growth engine, with revenue reaching $139.3 million for the full year, reflecting over 100% growth [14][18] - The company achieved financial self-sustainability in 2025, allowing for continued investment in its pipeline and commercial strategy [4][18] Revenue Performance - Total revenue for Q4 2025 was $85.8 million, representing a 43% increase year-over-year [13][14] - For the full year, Recorlev revenue was $139.3 million, Gvoke revenue was $94.1 million, and Keveyis revenue was $47.6 million [14][15] - The company expects total revenue for 2026 to be between $375 million and $390 million, indicating over 30% growth at the midpoint compared to 2025 [12][19] Product Development and Pipeline - The company plans to initiate a Phase III study for XP-8121 in the second half of 2026, which is anticipated to be a significant value creation inflection point [8][11] - XP-8121 is projected to address a significant unmet medical need and has the potential to generate $1 billion to $3 billion in peak revenue [10][11] - The company has a strong intellectual property foundation for Recorlev, with four Orange Book-listed patents running until March 2040 [6][5] Operational Strategy - The company has expanded its commercial team to enhance sales and patient support, nearly doubling its footprint in January 2025 [1][5] - Adjusted EBITDA for 2025 was $59.4 million, reflecting continued operating leverage and disciplined expense management [18][21] - The company plans to increase R&D expenses by approximately $25 million in 2026 to support the XP-8121 program [20][21] Market Position and Competitive Landscape - The company remains confident in its ability to defend Recorlev against patent infringement lawsuits, having filed against two ANDA filers [5][48] - The market for Recorlev is expected to continue expanding, with the company positioned to capture a larger share due to increased prescriber awareness and patient demand [1][39] - Gvoke and Keveyis are also expected to contribute steadily to revenue, with Gvoke anticipated to grow in the high single-digit to low double-digit range [36][37]

Core Insights - Xeris Biopharma reported significant revenue growth in Q4 and full year 2025, achieving financial self-sustainability and a strong operational foundation [6][5][18] Financial Performance - Fourth quarter revenue reached $85.8 million, a 43% year-over-year increase, while full-year revenue was $291.8 million, up 44% [5] - Adjusted EBITDA for the year was nearly $60 million, with a gross margin of 87% in Q4 and 85% for the full year, reflecting improvements driven by product mix [4][7] - Gvoke generated $24.6 million in Q4 and $94.1 million for the full year, with a 14% growth attributed to broad access and alignment with treatment guidelines [2] - Recorlev's revenue was $45.3 million in Q4 and $139.3 million for the full year, representing over 100% growth, with the patient base expanding to approximately 700 by year-end 2025 [3] Strategic Outlook - For 2026, Xeris projects total revenue between $375 million and $390 million, indicating over 30% growth at the midpoint, while maintaining adjusted EBITDA positivity despite increased R&D and SG&A investments [9][11] - The company plans to initiate phase III studies for its key pipeline program, XP-8121, in the second half of 2026, targeting a market of over 20 million patients [16][17] Product Development and Market Position - Recorlev is expected to be the primary growth driver, with ongoing investments in commercial expansion and patient support [12][10] - Xeris is confident in its intellectual property for Recorlev, holding four Orange Book-listed patents until March 2040 and orphan drug exclusivity through the end of 2028 [14] Competitive Landscape - The company anticipates typical seasonality in Q1, with payer and co-pay resets potentially slowing January sales before a rebound in February and March [13]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 grew 43% year-over-year to nearly $86 million, while full-year revenue increased by 44% to $292 million [5][6][15] - Adjusted EBITDA for Q4 was $25.1 million, an improvement of $16.8 million compared to the previous year, with full-year adjusted EBITDA at $59.4 million [18][19] - The company achieved net income for the first time on a full-year basis in 2025, marking a significant milestone in financial performance [19] Business Line Data and Key Metrics Changes - Recorlev revenue was $45.3 million in Q4 and $139.3 million for the full year, reflecting over 100% growth for both periods, driven by an expanding patient base [16][17] - Gvoke generated $24.6 million in Q4 and $94.1 million for the year, with steady prescription growth and broad access contributing to its performance [16][17] - Keveyis revenue was $12.8 million in Q4 and $47.6 million for the year, supported by an increase in the average number of patients on therapy [17] Market Data and Key Metrics Changes - The patient base for Recorlev nearly doubled to approximately 700 patients by the end of 2025, reflecting increased prescriber awareness and confidence [7] - Gvoke remains a life-saving product for diabetes patients, with continued alignment with treatment guidelines supporting its growth [9] - Keveyis continues to serve a small, underserved patient community, aligning with the company's mission to make a meaningful difference in rare diseases [10] Company Strategy and Development Direction - The company aims for rapid revenue growth and plans to invest in sales, patient support, and commercial infrastructure [12][20] - XP-8121 is expected to enter Phase 3 trials in the second half of 2026, with potential peak sales of $1 billion to $3 billion [11][12] - The company is committed to maintaining a strong balance sheet while making disciplined investments to support growth [19][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and momentum entering 2026, expecting total revenue between $375 million and $390 million, representing over 30% growth at the midpoint compared to 2025 [13][20] - The company anticipates remaining adjusted EBITDA positive while significantly increasing R&D and commercial investments [20][22] - Management highlighted the importance of a strong operating foundation and the potential for sustained long-term growth [19][70] Other Important Information - The company filed a patent infringement lawsuit against two ANDA filers to protect Recorlev, with confidence in its intellectual property [8][62] - Management emphasized the need for ongoing investments in data studies and patient support to drive Recorlev's growth [26] Q&A Session Summary Question: Insights on Recorlev expansion and operating leverage - Management noted the doubling of the commercial footprint and the need for additional resources to manage patient loads effectively [26][27] Question: Impact of IP litigation on business development - Management stated that the strategy for Recorlev remains unchanged and they are prepared for the litigation [31][32] Question: Guidance on capital deployment beyond 2026 - Management indicated a strong balance sheet and the potential for business development opportunities while remaining disciplined [33][34] Question: Revenue guidance by product for 2026 - Management expects Keveyis to flatten out, Gvoke to grow in the high single-digit to low double-digit range, and Recorlev to be the primary growth driver [40][41] Question: Concerns about generic competition for Recorlev - Management does not see generic Korlym as a risk, emphasizing the different approaches required for prescribing [50] Question: Updates on XP-8121 and FDA interactions - Management confirmed alignment with the FDA and readiness to initiate Phase 3 trials without regulatory gating issues [53]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 grew 43% year-over-year to nearly $86 million, while full-year revenue increased by 44% to $292 million [5][6][15] - Adjusted EBITDA for Q4 was $25.1 million, an improvement of $16.8 million compared to the previous year, and for the full year, it was $59.4 million [18][19] - The company achieved net income on a full-year basis for the first time in 2025, marking a significant milestone in financial performance [19] Business Line Data and Key Metrics Changes - Recorlev revenue was $45.3 million in Q4 and $139.3 million for the full year, reflecting growth of over 100% for both periods, driven by an expanding patient base [16][17] - Gvoke generated $24.6 million in Q4 and $94.1 million for the full year, with steady prescription growth and broad access contributing to its performance [16][17] - Keveyis revenue was $12.8 million in Q4 and $47.6 million for the year, supported by an increase in the average number of patients on therapy [17] Market Data and Key Metrics Changes - Recorlev ended the year with approximately 700 patients, nearly doubling the number from year-end 2024, indicating strong demand and prescriber awareness [7][8] - Gvoke's growth was supported by strong prescriber awareness and alignment with treatment guidelines, reinforcing its role as a reliable contributor [9] - Keveyis continues to serve a small, underserved patient community, aligning with the company's mission to make a meaningful difference in rare diseases [10] Company Strategy and Development Direction - The company aims to drive rapid revenue growth, advance its pipeline, and maintain a strong balance sheet while making targeted investments [12][19] - The strategic focus includes preparing for the phase III clinical trial of XP-8121, which is expected to be a significant value creation inflection point [10][12] - The company remains committed to achieving $1 billion in peak sales for Recorlev by 2035, with a strong intellectual property foundation supporting this goal [8][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's long-term strategy and highlighted the successful execution of strategic priorities in 2025 [4][6] - The outlook for 2026 anticipates total revenue between $375 million and $390 million, representing over 30% growth at the midpoint compared to 2025 [13][20] - Management emphasized the importance of maintaining disciplined investment prioritization to enhance operating leverage and support sustained performance [19][22] Other Important Information - The company filed a patent infringement lawsuit against two ANDA filers to protect its rights regarding Recorlev, reinforcing its confidence in its intellectual property [8][64] - The company plans to significantly increase R&D and SG&A expenses in 2026 to support growth initiatives and the upcoming phase III study for XP-8121 [21][22] Q&A Session Summary Question: Insights on Recorlev expansion and operating leverage - Management indicated that they have doubled their commercial footprint and will continue to invest in resources to manage patient loads effectively [26][27] Question: Thoughts on IP litigation and potential acquisitions - Management stated that their strategy remains unchanged and they are prepared for the IP litigation, with confidence in achieving $1 billion in sales for Recorlev by 2035 [28][32] Question: Guidance on capital deployment and gross margin evolution - Management noted that the strong balance sheet allows for disciplined business development and that gross margins are expected to improve due to favorable product mix [34][35] Question: Revenue guidance by product for 2026 - Management expects Keveyis to stabilize, Gvoke to grow in the high single-digit to low double-digit range, and Recorlev to be the primary growth driver [41][42] Question: Updates on XP-8121 and FDA interactions - Management confirmed alignment with the FDA and emphasized the importance of entering the phase III trial with a scaled-up go-to-market device [54][56]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 43% year-over-year to nearly $86 million, with full-year revenue increasing by 44% to $292 million [5][14] - Adjusted EBITDA for Q4 was $25.1 million, an improvement of $16.8 million compared to the previous year, with full-year adjusted EBITDA at $59.4 million [17][18] - The company reported net income for the first time on a full-year basis in 2025, reflecting improved financial health [18] Business Line Data and Key Metrics Changes - Recorlev revenue was $45.3 million in Q4 and $139.3 million for the full year, reflecting over 100% growth for both periods, driven by an expanding patient base [15][16] - Gvoke generated $24.6 million in Q4 and $94.1 million for the full year, with steady prescription growth and broad access [15][16] - Keveyis revenue was $12.8 million in Q4 and $47.6 million for the year, supported by an increase in the average number of patients on therapy [16] Market Data and Key Metrics Changes - Recorlev ended 2025 with approximately 700 patients, nearly doubling from year-end 2024, indicating strong market demand [6] - Gvoke remains a life-saving product for diabetes patients, with continued alignment with treatment guidelines contributing to its growth [8] - The company anticipates a significant market opportunity for XP-8121, targeting a peak revenue potential of $1 billion to $3 billion [11] Company Strategy and Development Direction - The company aims to drive rapid revenue growth, advance its pipeline, and maintain a strong balance sheet for future investments [11][18] - The strategic focus includes expanding the commercial team for Recorlev and preparing for the Phase 3 study of XP-8121 [10][11] - The company is committed to maintaining disciplined investment prioritization while enhancing operating leverage [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial self-sustainability and the ability to fund its strategy and pipeline [4][5] - The outlook for 2026 includes expected total revenue between $375 million and $390 million, representing over 30% growth at the midpoint compared to 2025 [11][19] - Management highlighted the importance of continued investment in R&D and commercial infrastructure to support growth [20] Other Important Information - The company filed a patent infringement lawsuit against two ANDA filers to protect its rights regarding Recorlev [7] - The company has four Orange Book-listed patents for Recorlev that run until March 2040, providing a strong IP foundation [7] Q&A Session Summary Question: Insights on Recorlev expansion and operating leverage - Management noted the recent doubling of the commercial footprint and the need for additional resources to manage patient loads effectively [25][26] Question: Impact of IP litigation on business development - Management reiterated that their strategy for Recorlev remains unchanged and they are prepared for the ongoing litigation [30][31] Question: Guidance on capital deployment beyond 2026 - Management indicated a strong balance sheet and the potential for business development opportunities, while emphasizing the strength of existing assets [32] Question: Revenue guidance by product for 2026 - Management expects steady contributions from Keveyis and Gvoke, with Recorlev being the primary growth driver [40] Question: Updates on XP-8121 and FDA interactions - Management confirmed alignment with the FDA and emphasized the importance of entering Phase 3 with a scaled-up commercial device [52] Question: Openness to settlement regarding Recorlev litigation - Management declined to comment on legal strategy but expressed confidence in their patent position [66]

Core Insights - Xeris Biopharma (XERS) is expected to report quarterly earnings of $0.03 per share, reflecting a 200% increase year-over-year [1] - Analysts forecast revenues of $81.43 million, indicating a 35.5% year-over-year growth [1] - The consensus EPS estimate has remained unchanged over the past 30 days, suggesting analysts' reassessment of projections [1] Revenue Estimates - Analysts estimate 'Product Revenue- Gvoke' will reach $26.45 million, a 13.7% increase from the previous year [4] - 'Product Revenue- Keveyis' is projected to be $43.67 million, showing a significant increase of 292.6% year-over-year [4] - 'Revenue- Royalty, contract and other' is expected to be $1.02 million, indicating a decline of 67.2% year-over-year [4] Additional Revenue Metrics - 'Revenue- Product revenue, net' is anticipated to be $81.19 million, reflecting a 42.4% increase from the prior-year quarter [5] - 'Product Revenue- Recorlev' is expected to be $11.07 million, showing a decrease of 51.1% year-over-year [5] - Xeris Biopharma shares have decreased by 7% in the past month, contrasting with the Zacks S&P 500 composite's increase of 0.6% [5]

Financial Data and Key Metrics Changes - Total product revenue for Q3 2025 exceeded $74 million, representing a 40% increase year over year [4] - The company raised the lower end of its full-year total revenue guidance to a range of $285-$290 million, indicating a 42% increase at the midpoint compared to 2024 [4][12] - Gross margin improved to 85%, driven primarily by an improved product mix [11] - For the first time in the company's history, it reported quarterly net income [9][11] Business Line Data and Key Metrics Changes - Recorlev generated revenue of $37 million in Q3, a year-over-year increase of 109%, with the average number of patients on therapy growing by 108% [5][10] - Gvoke delivered revenue of more than $25 million, up nearly 10% from the same period last year, driven by a 5% increase in total prescriptions [6][10] - Keveyis achieved quarterly revenue of approximately $12 million, supported by new patient additions [6][10] Market Data and Key Metrics Changes - The company continues to expand its prescriber base for Recorlev, reflecting strong demand in the hypercortisolemia and Cushing's syndrome market [5][7] - The average number of patients on therapy for Keveyis increased, indicating a healthy pace of new patient starts [10] Company Strategy and Development Direction - The company is focused on expanding its commercial footprint to capture significant opportunities for Recorlev while strengthening operational capabilities for scalable growth in 2026 and beyond [7] - The strategic expansion includes nearly doubling the sales and patient support teams [7] - The company is advancing its pipeline with XP-8121, a once-weekly subcutaneous form of levothyroxine, with plans to initiate a phase three clinical trial in the second half of 2026 [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for therapies and the company's ability to deliver strong performance [9][12] - The company anticipates continued growth for Recorlev, with expectations of it becoming a billion-dollar product [21] - Management emphasized the importance of maintaining positive adjusted EBITDA while making incremental investments in growth opportunities [12][24] Other Important Information - The company is committed to remaining adjusted EBITDA positive despite increased spending on R&D and SG&A [12][24] - Management highlighted the importance of a disciplined approach to investments in technology and infrastructure to support future growth [29] Q&A Session Summary Question: Impact of expanded sales force on Recorlev productivity - The sales force for Recorlev was increased by 50%, and productivity is expected to ramp up in the first half of the year [15][16] Question: Discontinuation rates for Recorlev - There have been no significant changes in dropout rates, with new patient starts overwhelming any metrics [19][20] Question: Competitive dynamics with potential new entrants - Management views the potential approval of competitors as an opportunity to expand the market for hypercortisolemia treatments [40][41] Question: Plans to target general practitioners for Recorlev - The company plans to expand its commercial footprint to include general practitioners as part of its data-driven approach [41][42] Question: Durability of the Keveyis franchise - The company continues to see strong performance from Keveyis, with ongoing efforts to support patient treatment and retention [45]

Core Viewpoint - Xeris Biopharma (XERS) shares experienced a significant increase of 14.2% to $9.27, driven by strong investor expectations regarding its growth prospects and an impressive trading volume [1][2]. Company Performance - The stock's recent price surge is linked to positive investor sentiment about Xeris' marketed drugs, including Recorlev, Gvoke, and Keveyis, which target specific medical conditions [2]. - Xeris is projected to report quarterly earnings of $0.01 per share, reflecting a year-over-year increase of 116.7%, with expected revenues of $74.35 million, up 37% from the previous year [3]. Earnings Estimates - The consensus EPS estimate for Xeris has been revised 60.7% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4]. - The strong earnings estimate revisions suggest potential for continued stock strength in the future [4]. Industry Context - Xeris Biopharma holds a Zacks Rank of 2 (Buy), indicating favorable market conditions compared to its industry peers [5]. - In contrast, Zoetis (ZTS), another company in the same medical-drugs industry, saw a slight decline of 0.9% in its stock price and has a Zacks Rank of 3 (Hold) [5][6].